Asian Pacific Journal of Cancer Prevention

  • 제13권11호
  • /
  • Pages.5399-5403
  • /
  • 2012
  • /
  • 1513-7368(pISSN)
  • /
  • 2476-762X(eISSN)
아시아태평양암예방학회 (Asian Pacific Journal of Cancer Prevention)
권호 표지
DOI QR코드

DOI QR Code

Serum Human Leukocyte Antigen-G and Soluble Interleukin 2 Receptor Levels in Acute Lymphoblastic Leukemic Pediatric Patients

  • Motawi, Tarek M.K. (Biochemistry Department, Faculty of Pharmacy, National Cancer Institute) ;
  • Zakhary, Nadia I. (Cancer Biology Department, National Cancer Institute) ;
  • Salman, Tarek M. (Biochemistry Department, Faculty of Pharmacy, National Cancer Institute) ;
  • Tadros, Samer A. (Biochemistry Department, Faculty of Pharmacy, National Cancer Institute)
  • 발행 : 2012.11.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Aims and Background: Human leukocyte antigen-G and interleukin-2 receptor play pivotal roles in the proliferation of lymphocytes, and thus generation of immune responses. Their overexpression has been evidenced in different malignant hematopoietic diseases. This study aimed to validate serum soluble human leukocyte antigen-G (sHLA-G) and serum soluble interleukin-2 receptor (sIL-2R) as an additional tool for the diagnosis and follow up of acute lymphoblastic leukemia (ALL). Subjects and Methods: Both markers were determined by ELISA in the serum of 33 ALL pediatric patients before treatment and after intensification phase of chemotherapy as well as in the serum of 14 healthy donors that were selected as a control group. Results: ALL patients showed abnormal CBC and high serum lactate dehydrogenase, which were improved after chemotherapy. Also, there was a non-significant increase in serum sHLA-G in ALL patients compared with the control group. However, after chemotherapy, sHLA-G was increased significantly compared with before treatment. On the other hand, serum sIL-2R in ALL patients was increased significantly compared with the control group. After chemotherapy, sIL-2R decreased significantly compared with before treatment. Conclusions: From these results it could be suggested that measurement of serum sHLA-G might be helpful in diagnosis of ALL, while sIL-2R might be useful in diagnosis and follow-up of ALL in pediatric patients.

키워드

참고문헌

  1. Arioz DT, Altindis M, Tokyol C, et al (2009). Human papillomavirus typing and soluble interleukin-2 receptor levels in female sex workers with a negative cervical smear result. Int J of Gynaecol Obstet, 106, 210-2. https://doi.org/10.1016/j.ijgo.2009.04.005
  2. Bien E, Balcerska A (2009). Serum soluble interleukin-2 receptor, beta2-microglobulin, lactate dehydrogenase and erythrocyte sedimentation rate in children with Hodgkin's lymphoma. Scand J Immunol, 70, 490-500. https://doi.org/10.1111/j.1365-3083.2009.02313.x
  3. Bien E, Balcerska A (2008). Serum soluble interleukin 2 receptor alpha in human cancer of adults and children: a review. Biomarkers, 13, 1-26. https://doi.org/10.1080/13547500701674063
  4. Bien E, Balcerska A. (2003). Interleukin 2 receptor-the structure, function and clinical significance in malignant diseases of adults and children. Postepy Hig Med Dosw, 57, 669-83.
  5. Brito-Babapulle F (2003). The eosinophilias, including the idiopathic hypereosinophilic syndrome. Br J Haematol, 121, 203-23. https://doi.org/10.1046/j.1365-2141.2003.04195.x
  6. Cervera I, Herraiz MA, Penaloza J, Vidart J, Martinez-Laso J (2010). A new allele, HLA-G*010120, is generated by a recombination event between HLA-G*01010101/02 and HLA-G*01010201. Tissue Antigens, 75, 738-40. https://doi.org/10.1111/j.1399-0039.2010.01455.x
  7. Eiji O, Tasuke H, Katsumi O, et al (2000). Clinical utility of soluble interleukin-2 receptor in patients with acute lymphoblastic leukemia. Jpn J Med Technol, 49, 1576-9.
  8. Elattar I (2007). Cancer statistics, NCI, Egypt 2002-2005.
  9. Faderl S, O'Brien S, Pui CH, et al (2010). Adult acute lymphoblastic leukemia: concepts and strategies. Cancer, 1, 1165-76.
  10. Fainardi E, Castellazzi M, Stignani M, et al (2011). Emerging topics and new perspectives on HLA-G. Cell Mol Life Sci, 68, 433-51. https://doi.org/10.1007/s00018-010-0584-3
  11. Garcia-Tunon I, Ricote M, Ruiz A, et al (2004). Interleukin-2 and its receptor complex (${\alpha}$, ${\beta}$ and ${\gamma}$ chains) in in situ and infiltrative human breast cancer: an immunohistochemical comparative study. Breast Cancer Res, 6, 1-7. https://doi.org/10.1186/bcr820
  12. Gonzalez A, Rebmann V, LeMaoult J, et al (2012). The immunosuppressive molecule HLA-G and its clinical implications. Crit Rev Clin Lab Sci, 49, 63-84. https://doi.org/10.3109/10408363.2012.677947
  13. Hafiz MG, Rahman MM, Mannan MA (2008). Serum lactate dehydrogenase as a prognostic marker of childhood acute lymphoblastic leukemia. Mymensingh Med J, 17, 169-73.
  14. HoWangYin K, Caumartin J, Favier B, et al (2011). Proper regrafting of Ig-like transcript 2 after trogocytosis allows a functional cell-cell transfer of sensitivity. J Immunol, 186, 2210-8. https://doi.org/10.4049/jimmunol.1000547
  15. HoWangYin KY, Alegre E, Daouya M, et al (2010). Different functional outcomes of intercellular membrane transfers to monocytes and T cells. Cell Mol Life Sci, 67, 1133-45. https://doi.org/10.1007/s00018-009-0239-4
  16. Jo SA, Hwang SH, Chang CL, et al (2010). Clinical relevance of elevated levels of serum soluble interleukin-2 receptor alpha (sIL-2R${\alpha}$) in patients with non-Hodgkin's lymphoma. Korean J Lab Med, 30, 600-5. https://doi.org/10.3343/kjlm.2010.30.6.600
  17. Kasprzak A, Olejniczak K, Przybyszewska W, Zabel M (2007). Cellular expression of interleukin 2 (IL-2) and its receptor (IL-2R, CD25) in lung tumours. Folia Morphol (Warsz), 66, 159-66.
  18. Katsuya H, Yamanaka T, Ishitsuka K, et al (2012). Prognostic index for acute-and lymphoma-type adult T-cell leukemia/ lymphoma. J Clin Oncol, 30, 1635-40. https://doi.org/10.1200/JCO.2011.38.2101
  19. Kitaoka S, Shiota G, Kawasaki H. (2003). Serum levels of interleukin-10, interleukin-12 and soluble interleukin-2 receptor in chronic liver disease type C. Hepatogastroenterology, 50, 1569-74.
  20. Ksouri H, Bardi R, Mellouli F, Bejaoui M (2009). HLA-G: an immunoregulatory non classical class I HLA molecule. Arch Inst Pasteur Tunis, 86, 27-38.
  21. Le Discorde M, Moreau P, Sabatier P, Legeais JM and Carosella ED (2003). Expression of HLA-G in human cornea, an immune-privileged tissue. Hum Immunol, 64, 1039-44. https://doi.org/10.1016/j.humimm.2003.08.346
  22. Ling JY, Sun XF, Yan SL, et al (2007). Bone marrow immunophenotypes of 112 cases of lymphoid system malignant diseases. Ai Zheng, 26, 418-22.
  23. Mallet V, Blaschitz A, Crisa L, et al (1999). HLA-G in the human thymus: a subpopulation of medullary epithelial but not CD83 dendritic cells expresses HLA-G as a membranebound and soluble protein. Int Immunol, 11, 889-98. https://doi.org/10.1093/intimm/11.6.889
  24. Mitsdoerffer M, Schreiner B, Kieseier BC, et al (2005). Monocyte-derived HLA-G acts as a strong inhibitor of autologous CD4 T cell activation and is upregulated by interferon-beta in vitro and in vivo: rationale for the therapy of multiple sclerosis. J Neuroimmunol, 159, 155-64. https://doi.org/10.1016/j.jneuroim.2004.09.016
  25. Moon Y, Kim Y, Kim M, et al (2004). Plasma soluble interleukin-2 receptor (sIL-2R) levels in patients with acute leukemia. Ann Clin Lab Sci, 34, 410-5.
  26. Nakase K, Tsuji K, Tamaki S, et al (2005). Elevated levels of soluble interleukin-2 receptor in serum of patients with hematological or non-hematological malignancies. Cancer Detect and Prev, 29, 256-9. https://doi.org/10.1016/j.cdp.2005.03.001
  27. Pavlidis NA, Manoussakis MN, Germanidis GS, Moutsopoulos HM (1992). Serum soluble interleukin-2 receptors in B-cell lymphoproliferative malignancies. Med Pediatr Oncol, 20, 26-31.
  28. Pistoia V, Morandi F, Wang X, Ferrone S (2007). Soluble HLA-G: Are they clinically relevant. Semin Cancer Biol, 17, 469-79. https://doi.org/10.1016/j.semcancer.2007.07.004
  29. Pui CH (2006). Acute lymphoblastic leukemia, in Childhood Leukemias, 2nd ed. In: Pui CH. Cambridge University Press, New York, p 439.
  30. Pui CH, Evans WE (2006). Treatment of acute lymphoblastic leukemia. N Engl J Med, 354, 166-78. https://doi.org/10.1056/NEJMra052603
  31. Rebmann V, Switala M, Eue I, Grosse-Wilde H (2010). Soluble HLA-G is an independent factor for the prediction of pregnancy outcome after ART: a German multi-centre study. Hum Reprod, 25, 1691-8. https://doi.org/10.1093/humrep/deq120
  32. Rizzo R, Vercammen M, van de Velde H, Horn PA, Rebmann V (2011). The importance of HLA-G expression in embryos, trophoblast cells, and embryonic stem cells. Cell Mol Life Sci, 68, 341-52. https://doi.org/10.1007/s00018-010-0578-1
  33. Rouas-Freiss N, Moreau P, Ferrone S and Carosella ED (2005). HLA-G proteins in cancer: do they provide tumor cells with an escape mechanism? Cancer Res, 65, 10139-44. https://doi.org/10.1158/0008-5472.CAN-05-0097
  34. Sarmento-Ribeiro AB, Proenca MT, Sousa I, et al (2012). A possible role for oxidation stress in lymphoid leukaemias and therapeutic failure. Leuk Res, 36, 1041-8. https://doi.org/10.1016/j.leukres.2012.03.015
  35. Sheshgiri R, Rao V, Mociornita A, Ross HJ, Delgado DH (2010). Association between HLA-G expression and C4d staining in cardiac transplantation. Transplantation, 89, 480-1. https://doi.org/10.1097/TP.0b013e3181ca88d5
  36. Singer G, Rebmann V, Chen YC, et al (2003). HLA-G is a potential tumor marker in malignant ascites. Clin Cancer Res, 9, 4460-4.
  37. Wehner R, Dietze K, Bachmann M, Schmitz M (2011). The bidirectional crosstalk between human dendritic cells and natural killer cells. J Innate Immun, 3, 258-63. https://doi.org/10.1159/000323923
  38. Wiendl H, Feger U, Mittelbronn M, et al (2005). Expression of the immune-tolerogenic major histocompatibility molecule HLA-G in multiple sclerosis: implications for CNS immunity. Brain, 128, 2689-704. https://doi.org/10.1093/brain/awh609
  39. Yan WH (2010). HLA-G expression in hematologic malignancies. Expert Rev Hematol, 3, 67-80. https://doi.org/10.1586/ehm.09.72
  40. Yang J, Zhao SL, Yang XL (2012). Expression of HLA-G and IL-10 in patients with acute leukemia. Zhonghua Xue Ye Xue Za Zhi, 33, 135-7.

피인용 문헌

  1. Going back to class I: MHC and immunotherapies for childhood cancer vol.62, pp.4, 2014, https://doi.org/10.1002/pbc.25359
  2. Comparison of saliva interleukin-2 concentration to the condition of gums in children with acute lymphoblastic leukaemia during anti-tumour treatment vol.76, pp.1, 2015, https://doi.org/10.1007/s00280-015-2750-7